Article PDF first page preview

First page of Acute Antibody-Mediated Rejection Associated with Anti-MICA Antibodies in Long-Term Kidney Transplant: A Case Study

Introduction: Advances in immunosuppressive therapy have improved kidney transplant outcomes; however, antibody-mediated rejection (ABMR) still affects graft survival. Herein, we present a case of a 46-year-old woman who experienced acute ABMR despite stable long-term graft function following kidney transplantation. Case Presentation: At 28 years of age, she underwent a blood-type-compatible living kidney transplant from her father. Eighteen years later, she was admitted to the hospital with a fever and sore throat, raising suspicion of a respiratory infection. Given the rapid deterioration of renal function following hospitalisation, a biopsy was conducted. The findings showed diffuse glomerulitis and peritubular capillaritis, along with focal observations of endoarteritis, glomerular thrombi, and interstitial haemorrhage, consistent with active ABMR. She was treated with methylprednisolone pulse therapy and intravenous immunoglobulin, which induced gradual recovery. Screening tests for anti-human leukocyte antigen (HLA) antibodies yielded negative results. However, tests for non-HLA antibodies detected the presence of anti-major histocompatibility complex class I chain-related gene A (MICA) antibodies in the blood sample prior to the onset of rejection. Notably, at the time of rejection, anti-MICA antibodies were not detectable in the blood; nevertheless, they were subsequently found to be positive 10 months later. These antibodies may have been sequestered within tissues, rendering them undetectable in the bloodstream. Conclusion: Anti-MICA antibodies have previously been implicated in ABMR; however, this case highlights their role in late-onset rejection after prolonged graft stability. This case underscores the importance of non-HLA donor-specific antibody tests when ABMR occurs in a recipient lacking anti-HLA antibodies.

Journal Section:
Clinical Practice
This content is only available via PDF.
S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.